

Special Issue

Molecular Research on Colorectal Cancer

Message from the Guest Editors

Colorectal Cancer (CRC) is the third most common malignancy in humans. The incidence of CRC varies widely around the world, as the risk of developing this disease is influenced by environmental, genetic and lifestyle factors. Currently, primary prevention and early detection appear to be necessary weapons to increase survival rates. Many risk factors can alter the microbiome composition and deregulate immune responses by inducing inflammation. In the colonic epithelium, chronic inflammation and reactive oxygen species (ROS) production impair pathways deputed to tissue turnover and DNA damage repair through metabolic alterations in the intestinal microenvironment. Adenomas originate from altered functional homeostasis of the intestinal epithelium and are the main precursor of CRC in both high-risk family groups and the general population. Molecular characterization of the interactions between tumor cells and the microenvironment, during tumor progression, could allow the identification of biomarkers, useful for preventive approaches to CRC.

Guest Editors

Dr. Teresa Catalano

Department of Clinical and Experimental Medicine, University of Messina, via Consolare Valeria, 98125 Messina, Italy

Dr. Gitana Maria Aceto

Unit of Experimental Pathology, Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti-Pescara, 66100 Chieti, Italy

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/136792

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).